Prof. Satoshi KURODAJapan
Toyama University Hospital
| 2012 to present | Professor and Chairman, Department of Neurosurgery, University of Toyama, Toyama, Japan |
| 1986 - 1995 | Department of Neurosurgery, Hokkaido University, Sapporo, Japan |
| 1995 - 1997 | Wallenberg Neuroscience Center, Lund University, Lund, Sweden |
| 1998 - 2007 | Assistant Professor, Department of Neurosurgery, Hokkaido University, Sapporo, Japan |
| 2007 - 2012 | Associate Professor, Department of Neurosurgery, Hokkaido University, Sapporo, Japan |
cerebrovascular surgery, moyamoya disease, brain tumor, spinal disorders, cerebral blood flow and metabolism, non-human experiments
He is a skillful neurosurgeon and has operated on huge numbers of patients with cerebrovascular diseases for these 37 years. He is mainly interested in open surgery for cerebrovascular diseases, including carotid stenosis/occlusion, cerebral aneurysm, and moyamoya disease. He also has many experiences of surgery for brain tumor, spinal cord disorders, and trigeminal neuralgia/facial spasm. Total number of surgeries for these 10 years is over 2,000. His scientific interest is focused on basic and clinical research on cerebral hemodynamics and metabolism, cerebral ischemia, cell therapy for CNS disorders. He has conducted several multi-center clinical studies in Japan. He has published over 380 English-written articles that can be found in PubMed website.
Impact factor; 1,005 (1986-2024)
Citation; 19,115
h-index; 72
International collaboration on the diagnosis and treatment of moyamoya disease
1108 15:20-15:30
Cerebrovascular/304B
The author is a Chair of the Research Committee on Moyamoya Disease in Japan. Previously, the committee established the diagnosis criteria in 1978 and have repeated the revision according to new knowledge on the pathophysiology and imaging studies. However, I believe that we should widely discuss with international colleagues to develop a set of diagnostic criteria that is acceptable to everyone in the world. Treatment guidelines have been published in US, Europe, and Japan, which should be unified over the world. Currently, several countries are planning to set up databases and biobanks for moyamoya disease, but these should be designed from the beginning to allow for international collaboration.
Trans-nasal transplantation of stem cell
1108 16:20-16:30
Cerebrovascular/304B
Transnasal route is a novel, non-invasive, and alternative delivery route of drugs and stem cells. Here, we present the efficacy of transnasal transplantation of multi-potent stem cells, human Muse cells, for cerebral infarct model of mice. We transplanted Muse cells, mesenchymal stromal cells (MSCs), or vehicle via transnasal route at 7 days after the onset of middle cerebral artery occlusion (MCAO) of the mice. Transnasal transplantation of Muse cells, but not of MSCs, significantly promoted the recovery of motor function. Histological analysis revealed that the engrafted Muse cells were widely distributed in the peri-infarct area and many of them differentiated into the neurons or oligodendrocytes. Transnal delivery of stem cells is a promising delivery route in regenerative medicine for brain disorders.